Barriers to Axsome AXS-07 migraine treatment beyond FDA approval, its

Central nervous system (CNS) specialist Axsome Therapeutics (Nasdaq: AXSM) expects to receive a full response letter (CRL) from the FDA due to chemistry, manufacturing and control (CMS) issues recently revealed during of the FDA’s review of its New Drug Application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraine headaches.

According to the report by industry analyst firm GlobalData, “Migraine Drug…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.

Comments are closed.